secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantheus Holdings, Inc. (LNTH)
CIK:        0001521036
Form:       8-K
Filed at:   2026-11-09T22:40:18+00:00
Accession:  0001193125-26-453913
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Lantheus to sell CDMO business and Springfield, NJ plant to PharmaLogic; signs Lu-177 dotatate supply deal
--------------------------------------------------------------------------------

- Definitive agreement dated Nov. 8, 2026 to sell Lantheus's contract development and manufacturing organization (CDMO) business and its Springfield, New Jersey facility to PharmaLogic Holdings Corp.
- No purchase price or other financial terms disclosed; closing is subject to customary closing conditions and regulatory approvals.
- Under a long-term supply agreement, PharmaLogic's therapeutic CDMO franchise Agilera will manufacture lutetium Lu 177 dotatate for Lantheus.
- Lantheus will provide certain transition services to PharmaLogic immediately after closing.
- Company flags risks that conditions may not be satisfied and that anticipated benefits may take longer to realize or involve unexpected costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1521036/000119312526453913/0001193125-26-453913-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1521036/000119312526453913/d166239d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-453913

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer